Skip to main content

Table 2 Incidence of resistant E. cloacae in ICU 1 and 2

From: Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract

  Selection ICU 1 ICU 2 Period
   All admissions Admissions > 48 h All admissions Admissions > 48 h  
Admissions (n) All 9418 2731 3624 884 1 Jan 2007–1 Nov 2014
Patients (n) 8073 2301 3257 836 1 Jan 2007–1 Nov 2014
On admission MREb 58a 25a 1 Jan 2007–1 Nov 2014
Acquisitions (n) 134 20 1 Jan 2007–1 Nov 2014
Mean incidence (acquisitions/DAR) MREb 4.60 (69/14977) 1.85 (6/3248) 1 Jan 2011–1 Nov 2014
Tobramycin I or R 4.95 (130/26265) 2.74 (20/7312) 1 Jan 2007–1 Nov 2014
Colistin R 5.02 (81/16139) 2.28 (10/4386) 1 Jan 2010–1 Nov 2014
ESBL production 4.64 (58/12489) 1.88 (6/3200) 1 Jan 2011–1 Nov 2014
  1. DAR days at risk, ESBL extended-spectrum beta-lactamase, I intermediate, ICU intensive care unit, MREb extended-spectrum beta-lactamase production and/or tobramycin non-susceptible and/or colistin-resistant, n number, R resistant. Colistin susceptibility was documented since December 2009 and presence of ESBL since January 2011
  2. aThese numbers include patients transmitted between the two ICUs. In total in 61 ICU admissions MREb was detected before or on admission